Dutasteride News and Research

RSS

Ethacrynic acid, a diuretic drug with potential anti-SARS-CoV-2 activity

A study published recently in the journal Viruses has identified a potent diuretic ethacrynic acid as an efficient inhibitor of the main protease of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This drug can be potentially repurposed to treat coronavirus disease 2019 (COVID-19).

20 Jan 2021

Prostate drugs linked to increased risk of developing type 2 diabetes

Researchers say patients should continue to take the drugs, which are commonly prescribed to older men, but warn they may need additional health checks.

11 Apr 2019

Use of 5ARIs for prostatic enlargement not linked to increased suicide risk in older men

Using 5α- reductase inhibitors was not associated with increased suicide risk in a group of older men but risks for self-harm and depression were increased during the 18 months after medication initiation, although "the relatively small magnitude of these risks should not dissuade physicians from prescribing these medications in appropriate patients," according to an article published online by JAMA Internal Medicine.

20 Mar 2017

Prolonged exposure to male hormone blockers increases risk of persistent erectile dysfunction

Men with longer exposure to the drugs finasteride and dutasteride had a higher risk of getting persistent erectile dysfunction than men with less exposure, reports a new Northwestern Medicine study.

9 Mar 2017

Erectile dysfunction drugs do not play role in preventing prostate cancer, study shows

While some previous studies have indicated that taking erectile dysfunction (ED) drugs may reduce the likelihood of developing prostate cancer, new research published in The Journal of Urology found that these drugs do not play a role in preventing prostate cancer.

2 Aug 2016

Impax releases generic version of dutasteride capsules, 0.5 mg

Impax Laboratories, Inc. today announced that on November 20, the Company's development and manufacturing partner received final approval by the U.S. Food and Drug Administration for a generic version of dutasteride capsules, 0.5 mg.

24 Nov 2015

Increased inflammation in prostate may predict reduced risk for cancer

Doctors at the North Shore-LIJ Health System have discovered that increased inflammation in the prostate may predict reduced risk for prostate cancer. The findings are published online in CANCER.

9 Dec 2013

Dutasteride decreases risk of biopsy detectable prostate cancer by 22.8%

The four-year REDUCE (REduction by DUtasteride of prostate Cancer Events) clinical study evaluated prostate cancer risk reduction in men taking dutasteride, a 5-alpha-reductase inhibitor (5ARI) typically used to treat enlarged prostate.

22 Jan 2013

Dutasteride delays PSA progression

The 5α-reductase inhibitor, dutasteride, delays the clinical progression of prostate cancer in patients with prostate-specific antigen levels that have failed to reduce adequately following radical therapy for localized disease, report researchers.

28 Nov 2012

Contrast-enhanced ultrasound effective in diagnosing men with high-grade prostate cancer

Contrast-enhanced ultrasound was found to better detect high-grade prostate cancer than conventional methods, making it a more appropriate approach for screening clinically important cancers and monitoring low-risk ones with less biopsies, researchers from Thomas Jefferson University and Hospitals conclude in a phase III study published online in September in the Journal of Urology.

28 Sep 2012

Combination of novel drug therapy and PSA test can effectively detect prostate cancer

Researchers have successfully developed and tested a new prostate cancer screening method that uses the combined power of a novel drug therapy and changes in PSA levels over time to identify men with a high PSA who are more likely to have aggressive prostate cancer despite negative biopsies.

12 Aug 2012

Researchers develop and test new prostate cancer screening method

9 Aug 2012

Wake Forest, UCSD develop new genetic test for prostate cancer

Karim Kader, MD, PhD, associate clinical professor at the UC San Diego School of Medicine, together with a team of researchers from Wake Forest University School of Medicine, have developed a genetic test to predict a man's risk for prostate cancer. Use of the test could reduce the need for repeat biopsies in men who have had a negative biopsy.

18 Jul 2012

Link between coronary artery disease and prostate cancer

In a large analysis of men participating in a prostate drug trial, researchers at the Duke Cancer Institute found a significant correlation between coronary artery disease and prostate cancer, suggesting the two conditions may have shared causes.

8 Feb 2012

Dutaseride may help prevent progression of early stage prostate cancer: Study

A new study suggests that men with early stage prostate cancer may benefit with drugs that can slow or stop the cancer’s progress. Less than 10 percent of the 100,000 men each year who are diagnosed with early-stage prostate cancer and have the option of leaving the cancer in place. Rest get it removed using surgery or radiation. But those treatments can have serious side effects like impotence and incontinence.

24 Jan 2012

KSU professor turns to nutrition to tackle prostate cancer

A Kansas State University professor is turning to nutrition to tackle prostate cancer. Brian Lindshield, assistant professor of human nutrition, is helping men make more informed diet decisions by studying foods and dietary supplements that may reduce the risk of prostate cancer. Prostate cancer is one of the most common forms of cancer among men in the United States.

24 Jan 2012

Dutasteride delays prostate cancer progression in men

For men diagnosed with low-risk, localized prostate cancer, being treated with the drug dutasteride delays disease progression and initiating active treatment, and also reduces anxiety, show the results of a three-year international clinical trial led by Dr. Neil Fleshner, Head of the Division of Urology, University Health Network.

24 Jan 2012

Impax confirms JALYN patent challenge

Impax Laboratories, Inc. today confirms that it has initiated a challenge of the patents listed in connection with JALYN capsules.

13 Sep 2011

GlaxoSmithKline files suit against Watson over generic JALYN

Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc. - Florida, filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market dutasteride and tamsulosin hydrochloride capsules.

25 Jul 2011

Scientists identify molecular mechanism behind alcohol-induced blackouts

A person who drinks too much alcohol may be able to perform complicated tasks, such as dancing, carrying on a conversation or even driving a car, but later have no memory of those escapades. These periods of amnesia, commonly known as "blackouts," can last from a few minutes to several hours.

7 Jul 2011